| Late Breaking Abstract LB2365. TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL
Dr Barbara Eichhorst, The University of Cologne, Cologne, Germany
Recorded @ Vienna Messe Center, June 11, 2022